FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058931815> ?p ?o ?g. }

• W2058931815 endingPage "514" @default.
• W2058931815 startingPage "509" @default.
• W2058931815 abstract "Purpose To provide a perspective on the impact of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) on future clinical practices. Design Interpretation of trial outcomes relative to clinical use of neovascular age-related macular degeneration (AMD) treatments, assessment of the influence of study design and execution on results, and review of unanalyzed safety data in the online supplement. Methods Expert opinion. Results The CATT study supports the selection of either ranibizumab or bevacizumab for treatment of AMD based on factors other than efficacy, such as cost, because monthly administration of bevacizumab was noninferior to the reference treatment of monthly ranibizumab in improving visual acuity at 1 year. Visual acuity results for bevacizumab as needed were inconclusive for noninferiority relative to monthly administration of either drug. The secondary outcome of decrease in thickness at the foveal center as measured by time-domain optical coherence tomography significantly favored the monthly ranibizumab group vs the bevacizumab-as-needed group but is more difficult to interpret as it did not correlate with visual acuity and is less appropriate for a noninferiority design. Bevacizumab groups had a statistically higher observed risk of serious adverse events; however, scrutiny of the online supplements shows similar numbers of cardiac and neurologic events in bevacizumab and ranibizumab users. Information regarding fellow eye treatment with anti-VEGF agents was not given. Conclusions CATT provides the first level I evidence for bevacizumab in a large number of patients with neovascular AMD. The trial supports use of either drug as primary therapy and suggests that modification of monthly dosing regimens is feasible. A difference in cardiovascular safety between the 2 drugs was not apparent on inspection of the supplementary safety data. To provide a perspective on the impact of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) on future clinical practices. Interpretation of trial outcomes relative to clinical use of neovascular age-related macular degeneration (AMD) treatments, assessment of the influence of study design and execution on results, and review of unanalyzed safety data in the online supplement. Expert opinion. The CATT study supports the selection of either ranibizumab or bevacizumab for treatment of AMD based on factors other than efficacy, such as cost, because monthly administration of bevacizumab was noninferior to the reference treatment of monthly ranibizumab in improving visual acuity at 1 year. Visual acuity results for bevacizumab as needed were inconclusive for noninferiority relative to monthly administration of either drug. The secondary outcome of decrease in thickness at the foveal center as measured by time-domain optical coherence tomography significantly favored the monthly ranibizumab group vs the bevacizumab-as-needed group but is more difficult to interpret as it did not correlate with visual acuity and is less appropriate for a noninferiority design. Bevacizumab groups had a statistically higher observed risk of serious adverse events; however, scrutiny of the online supplements shows similar numbers of cardiac and neurologic events in bevacizumab and ranibizumab users. Information regarding fellow eye treatment with anti-VEGF agents was not given. CATT provides the first level I evidence for bevacizumab in a large number of patients with neovascular AMD. The trial supports use of either drug as primary therapy and suggests that modification of monthly dosing regimens is feasible. A difference in cardiovascular safety between the 2 drugs was not apparent on inspection of the supplementary safety data." @default.
• W2058931815 created "2016-06-24" @default.
• W2058931815 creator A5011342936 @default.
• W2058931815 creator A5052637906 @default.
• W2058931815 creator A5071115321 @default.
• W2058931815 creator A5091788169 @default.
• W2058931815 date "2011-10-01" @default.
• W2058931815 modified "2023-10-15" @default.
• W2058931815 title "How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact Clinical Care" @default.
• W2058931815 cites W1481978003 @default.
• W2058931815 cites W1601975653 @default.
• W2058931815 cites W1802218256 @default.
• W2058931815 cites W1975926216 @default.
• W2058931815 cites W1980725734 @default.
• W2058931815 cites W1984142967 @default.
• W2058931815 cites W1995067794 @default.
• W2058931815 cites W1995708259 @default.
• W2058931815 cites W2011764310 @default.
• W2058931815 cites W2020050260 @default.
• W2058931815 cites W2021496037 @default.
• W2058931815 cites W2023523208 @default.
• W2058931815 cites W2033245558 @default.
• W2058931815 cites W2038006647 @default.
• W2058931815 cites W2058775052 @default.
• W2058931815 cites W2067071284 @default.
• W2058931815 cites W2069838435 @default.
• W2058931815 cites W2072033476 @default.
• W2058931815 cites W2080886828 @default.
• W2058931815 cites W2085712747 @default.
• W2058931815 cites W2087780877 @default.
• W2058931815 cites W2091989599 @default.
• W2058931815 cites W2096735172 @default.
• W2058931815 cites W2121621777 @default.
• W2058931815 cites W2124415048 @default.
• W2058931815 cites W2143874967 @default.
• W2058931815 cites W2148994564 @default.
• W2058931815 cites W2160726762 @default.
• W2058931815 cites W2162731664 @default.
• W2058931815 cites W2233259956 @default.
• W2058931815 cites W2915852396 @default.
• W2058931815 cites W4237695591 @default.
• W2058931815 doi "https://doi.org/10.1016/j.ajo.2011.07.004" @default.
• W2058931815 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4559340" @default.
• W2058931815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21961847" @default.
• W2058931815 hasPublicationYear "2011" @default.
• W2058931815 type Work @default.
• W2058931815 sameAs 2058931815 @default.
• W2058931815 citedByCount "16" @default.
• W2058931815 countsByYear W20589318152012 @default.
• W2058931815 countsByYear W20589318152013 @default.
• W2058931815 countsByYear W20589318152014 @default.
• W2058931815 countsByYear W20589318152015 @default.
• W2058931815 countsByYear W20589318152017 @default.
• W2058931815 countsByYear W20589318152018 @default.
• W2058931815 countsByYear W20589318152019 @default.
• W2058931815 countsByYear W20589318152023 @default.
• W2058931815 crossrefType "journal-article" @default.
• W2058931815 hasAuthorship W2058931815A5011342936 @default.
• W2058931815 hasAuthorship W2058931815A5052637906 @default.
• W2058931815 hasAuthorship W2058931815A5071115321 @default.
• W2058931815 hasAuthorship W2058931815A5091788169 @default.
• W2058931815 hasBestOaLocation W20589318152 @default.
• W2058931815 hasConcept C118487528 @default.
• W2058931815 hasConcept C126322002 @default.
• W2058931815 hasConcept C197934379 @default.
• W2058931815 hasConcept C2776403814 @default.
• W2058931815 hasConcept C2776694085 @default.
• W2058931815 hasConcept C2777802072 @default.
• W2058931815 hasConcept C2778257484 @default.
• W2058931815 hasConcept C2781100027 @default.
• W2058931815 hasConcept C535046627 @default.
• W2058931815 hasConcept C71924100 @default.
• W2058931815 hasConceptScore W2058931815C118487528 @default.
• W2058931815 hasConceptScore W2058931815C126322002 @default.
• W2058931815 hasConceptScore W2058931815C197934379 @default.
• W2058931815 hasConceptScore W2058931815C2776403814 @default.
• W2058931815 hasConceptScore W2058931815C2776694085 @default.
• W2058931815 hasConceptScore W2058931815C2777802072 @default.
• W2058931815 hasConceptScore W2058931815C2778257484 @default.
• W2058931815 hasConceptScore W2058931815C2781100027 @default.
• W2058931815 hasConceptScore W2058931815C535046627 @default.
• W2058931815 hasConceptScore W2058931815C71924100 @default.
• W2058931815 hasFunder F4320306811 @default.
• W2058931815 hasIssue "4" @default.
• W2058931815 hasLocation W20589318151 @default.
• W2058931815 hasLocation W20589318152 @default.
• W2058931815 hasLocation W20589318153 @default.
• W2058931815 hasLocation W20589318154 @default.
• W2058931815 hasOpenAccess W2058931815 @default.
• W2058931815 hasPrimaryLocation W20589318151 @default.
• W2058931815 hasRelatedWork W1507570872 @default.
• W2058931815 hasRelatedWork W1663750035 @default.
• W2058931815 hasRelatedWork W2014260690 @default.
• W2058931815 hasRelatedWork W2024548441 @default.
• W2058931815 hasRelatedWork W2052958850 @default.
• W2058931815 hasRelatedWork W2079794035 @default.
• W2058931815 hasRelatedWork W2124415048 @default.
• W2058931815 hasRelatedWork W2343066505 @default.

• next